PR Newswire: news distribution, targeting and monitoring
2014

PharmaPoint: Alzheimer's Disease - US Drug Forecast and Market Analysis to 2022

Share with Twitter Share with LinkedIn

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Alzheimer's Disease - US Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01658530/PharmaPoint-Alzheimer's-Disease---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

 

PharmaPoint: Alzheimer's Disease - US Drug Forecast and Market Analysis to 2022

 

Summary

 

GlobalData has released its new Country report, "PharmaPoint: Alzheimer's Disease - US Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

 

In recent years, the US has given AD the attention it deserves, and we expect that this will result in a push for increased rates of diagnosis. Because the "Baby-Boomer" generation is entering into its senior years, the AD market will see significant growth throughout the forecast period. New treatments anticipated for patients with presymptomatic AD or MCI will also increase the size of the market, since these populations were not targeted with the available symptomatic treatments. GlobalData will provide estimates for the approximate size of these populations, which are slated to integrate into the AD consumer market when disease-modifying drugs become available, in an upcoming report.

 

Scope

 

- Overview of Alzheimer's Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Alzheimer's Disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer's Disease

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in the US

Table of Contents

 

1 Table of Contents 5

1.1 List of Tables 9

1.2 List of Figures 11

2 Introduction 12

2.1 Catalyst 12

2.2 Related Reports 13

3 Disease Overview 15

3.1 Etiology and Pathophysiology 16

3.1.1 Etiology 16

3.1.2 Pathophysiology 19

3.2 Symptoms 31

4 Disease Management 33

4.1 Diagnosis 33

4.1.1 Probable Alzheimer's Disease Dementia 34

4.1.2 Possible AD Dementia 35

4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 35

4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 36

4.1.5 Preclinical AD 36

4.1.6 Mild Cognitive Impairment 37

4.2 Treatment Overview 39

4.3 United States 42

4.3.1 Diagnosis 42

4.3.2 Clinical Practice 42

5 Competitive Assessment 44

5.1 Overview 44

5.2 Strategic Competitor Assessment 44

5.3 Product Profiles - Major Brands 46

5.3.1 Aricept (donepezil hydrochloride) 46

5.3.2 Exelon (rivastigmine, rivastigmine tartrate) 50

5.3.3 Razadyne (galantamine hydrobromide) 55

5.3.4 Namenda (memantine hydrochloride) 59

6 Opportunity and Unmet Need 63

6.1 Unmet Needs Overview 63

6.1.1 Public Awareness 65

6.1.2 Specialized Institutions at Local Levels 66

6.1.3 Screening and Diagnosis 66

6.1.4 Early Intervention 67

6.1.5 Improved Clinical Trial Design 68

6.1.6 Effective Therapy 69

6.1.7 Behavioral Treatments 70

6.2 Gap Analysis 70

6.2.1 Disease Prevention 71

6.2.2 Diagnosis from Biomarkers 72

6.2.3 Behavioral Therapies 73

7 Pipeline Assessment 74

7.1 Overview 74

7.2 Early-Stage Pipeline Assessment 74

7.3 AD Pipeline by Mechanism of Action 77

7.4 Enzymatic Processing 77

7.5 Immunization 78

7.6 Anti-Aggregation 79

7.7 "Me-Too" 79

7.8 Novel Therapeutic Approaches 80

7.9 Technology Trends Analytic Framework 81

7.10 Promising Drugs in Clinical Development 82

7.10.1 Namenda XR 83

7.10.2 Arimenda 86

7.10.3 Gammagard Liquid 10% 89

7.10.4 Solanezumab 91

7.10.5 Gantenerumab 95

7.10.6 Crenezumab 100

7.10.7 TRx0237 103

7.10.8 MK-8931 107

7.10.9 EVP-6124 110

7.10.10 Lu AE58054 113

8 Market Outlook 117

8.1 United States 117

8.1.1 Forecast 117

8.1.2 Key Events 121

8.1.3 Drivers and Barriers 121

9 Appendix 125

9.1 Bibliography 125

9.2 Abbreviations 140

9.3 Methodology 147

9.4 Forecasting Methodology 147

9.4.1 Diagnosed AD patients 148

9.4.2 Percent Drug-treated Patients 148

9.4.3 Drugs Included in Each Therapeutic Class 149

9.4.4 Launch and Patent Expiry Dates 149

9.4.5 General Pricing Assumptions 150

9.4.6 Individual Drug Assumptions 150

9.4.7 Generic Erosion 156

9.4.8 Pricing of Pipeline Agents 156

9.5 Physicians and Specialists Included in this Study 158

9.6 About the Authors 159

9.6.1 Author 159

9.6.2 Global Head of Healthcare 160

9.7 About GlobalData 161

9.8 Disclaimer 161

 

 

 

List of Tables

 

Table 1:Symptoms of AD 32

Table 2:Guidelines for the Treatment of AD 39

Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 40

Table 4:Leading Branded Treatments for AD, 2013 45

Table 5:Product Profile - Aricept 48

Table 6:Aricept SWOT Analysis, 2013 50

Table 7:Product Profile- Exelon 52

Table 8:Exelon SWOT Analysis, 2012 55

Table 9:Product Profile - Razadyne 56

Table 10:Razadyne SWOT Analysis, 2013 59

Table 11:Product Profile- Namenda 60

Table 12:Namenda SWOT Analysis, 2013 62

Table 13:Overall Unmet Needs - Current Level of Attainment 64

Table 14:Clinical Unmet Needs - Gap Analysis, 2013 71

Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 81

Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 82

Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 83

Table 18:Product Profile - Namenda XR 84

Table 19:Namenda XR SWOT Analysis, 2013 86

Table 20:Product Profile - Arimenda 87

Table 21:Arimenda SWOT Analysis, 2013 89

Table 22:Product Profile - Gammagard Liquid 10% 90

Table 23:Product Profile - Solanezumab 92

Table 24:Solanezumab SWOT Analysis, 2013 95

Table 25:Product Profile - Gantenerumab 96

Table 26:Gantenerumab SWOT Analysis, 2013 99

Table 27:Product Profile - Crenezumab 100

Table 28:Crenezumab SWOT Analysis, 2013 103

Table 29:Product Profile - TRx0237 104

Table 30:TRx0237 SWOT Analysis, 2013 106

Table 31:Product Profile - MK-8931 107

Table 32:MK-8931 SWOT Analysis, 2013 110

Table 33:Product Profile - EVP-6124 111

Table 34:EVP-6124 SWOT Analysis, 2013 113

Table 35:Product Profile - Lu AE58054 114

Table 36:Lu AE58054 SWOT Analysis, 2013 116

Table 37:Sales Forecasts ($m) for AD in the United States, 2012-2022 119

Table 38:Key Events Impacting Sales for AD in the United States, 2012-2022 121

Table 39:AD Market in the United States - Drivers and Barriers, 2012-2022 121

Table 40:Key Launch Dates 149

Table 41:Key Patent Expirations 150

 

 

 

List of Figures

 

Figure 1:Atrophy of the Brain in AD 21

Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 23

Figure 3:Non-Amyloidogenic Metabolism of APP 25

Figure 4:Amyloidogenic Metabolism of APP 26

Figure 5:Neurofibrillary Tangles 28

Figure 6:Oxidative Damage Due to Free Radicals 30

Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 46

Figure 8:AD - Pipeline Drugs by Target, 2012 76

Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 82

Figure 10:Sales for AD in the United States by Drug Class, 2012-2022 120

 

 

To order this report: PharmaPoint: Alzheimer's Disease - US Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01658530/PharmaPoint-Alzheimer's-Disease---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release